Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Resmed (DE:RME)
FRANKFURT:RME
Resmed (RME) Stock Price & Analysis
2 Followers
RME Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€125.68 - €216.38
Previous Close€172.85
Volume0.00
Average Volume (3M)56.00
Market Cap
€25.62B
Enterprise Value€26.73B
Total Cash (Recent Filing)$210.25M
Total Debt (Recent Filing)$1.39B
Price to Earnings (P/E)N/A
Beta0.67
Next Earnings
Apr 25, 2024EPS Estimate
€1.82Last Dividend Ex-Date
Feb 07, 2024Dividend Yield1.01%
Share Statistics
EPS (TTM)N/A
Shares Outstanding147,088,888
10 Day Avg. Volume22
30 Day Avg. Volume56
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)24.94
Price to Sales (P/S)6.12
Price to Cash Flow (P/CF)25.00
P/FCF Ratio26.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.67
Enterprise Value/Gross Profit11.35
Enterprise Value/Ebitda19.25
Forecast
1Y Price Target
€173.93Price Target Upside0.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Resmed News
PremiumPre-Earnings
Resmed Inc (RMD) Q3 Earnings Cheat Sheet
Bulls Say, Bears Say
Bulls Say
Analyst's Rating And Market PotentialAnalysts maintain a positive Buy rating for RMD, underpinned by the large underdiagnosed OSA market and the absence of key competitors in the US, hinting at a strong growth trajectory for the company.
Clinical OutcomesRecent clinical data suggests a substantial number of patients could achieve OSA remission, potentially increasing the demand for RMD's solutions and enhancing its market position.
Market Share And Financial PerformanceRMD is well positioned to retain significant US market share gains, which could lead to sustained earnings growth and increased profitability through higher resupply rates.
Bears Say
Financial ImpactPhilips will need to conduct follow-up testing on 15 million devices and further site inspections, indicating significant costs and delays before re-entering the US market.
Product Efficacy ConcernsWeight loss drugs are not an obstructive sleep apnea cure, with only a small percentage of patients achieving a 'normal' AHI, which might not significantly reduce CPAP therapy usage and could impact mask revenue.
Regulatory ChallengesPhilips has agreed on the final terms of the CPAP consent decree, which includes a permanent injunction on new CPAP sales, reflecting FDA's view of Philips having multiple violations.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.14% Other Institutional Investors
98.86% Public Companies and
Individual Investors
RME FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest stock price was €125.68 and its highest was €216.38 in the past 12 months.
What is Resmed’s market cap?
Currently, no data Available
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Apr 25, 2024 which is 7 days ago.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Jan 24, 2024. The company reported €1.771 earnings per share for the quarter, beating the consensus estimate of €1.673 by €0.098.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed pays a Quarterly dividend of €0.45 which represents an annual dividend yield of 1.01%. See more information on Resmed dividends here
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is €1.82.
How many shares outstanding does Resmed have?
Currently, no data Available
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of €1.771 in its last earnings report, beating expectations of €1.673. Following the earnings report the stock price went up 6.512%.
Which hedge fund is a major shareholder of Resmed?
Among the largest hedge funds holding Resmed’s share is Greenvale Capital LLP. It holds Resmed’s shares valued at 95M.
---
Resmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€173.93 (0.63% Upside)
€173.93 (0.63% Upside)
Blogger Sentiment
Bullish
DE:RME Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.83%
12-Months-Change
Fundamentals
Return on Equity
21.66%
Trailing 12-Months
Asset Growth
3.43%
Trailing 12-Months
Company Description
Resmed
Founded in 1989, California-based ResMed, Inc. is a medical equipment company. The company is engaged in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through two segments: Sleep and Respiratory Care, and SaaS (Software as a Service).
---
RME Company Deck
---
RME Earnings Call
Q2 2024
0:00 / 0:00
---
RME Revenue Breakdown
53.77% Devices
34.44% Masks and other
11.79% Software as a Service
---
RME Stock 12 Months Forecast
Average Price Target
€173.93
▲(0.63% Upside)
Technical Analysis
Best Analysts Covering RME
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+0.91%
reiterated a buy rating 3 months ago
Copying David Low's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +0.91% per trade.
---